AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03546283
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients with hypertensive intracerebral hemorrhage will be randomized into giving placebos, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
Trial: NCT03546283
Drug: Cattle Encephalon Glycoside and Ignotin
RxNorm normalized name: anthraquinone glycoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients with hypertensive intracerebral hemorrhage will be randomized into giving CEGI, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
Trial: NCT01786603
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (looks like study drug but has no active ingredients) once a day for 12 months.
Trial: NCT04251910
Drug: Sublingual Placebo Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual placebo film that matches BXCL501
Trial: NCT01610245
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01610245
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04577846
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo capsule filled with inert material for the duration of the drains which usually is about 14 days.
Trial: NCT00532467
Drug: SRX251
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01003054
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg in 500 ml of normal saline over 4 hours on each of 2 consecutive days (day -3, -2)
Trial: NCT01024010
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04649723
Drug: SHR1459
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose, 200 mg, fasted.
Trial: NCT03340675
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching oral placebo
Trial: NCT03455491
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily during 3 days.
Trial: NCT01427985
Drug: Atropine, Fentanyl, Mivacurium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Atropin 10µg/kg~2. Mivacurium 200µg/kg immediately followed by~3. Fentanyl 2µg/kg
Trial: NCT01427985
Drug: Atropine, Fentanyl, Mivacurium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Atropin 10µg/kg~2. Fentanyl 2µg/kg, repeat max. two times~3. Mivacurium 200µg/kg
Trial: NCT00435838
Drug: No Intervention -- Observational study
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01750346
Drug: Topical acetyl hexapeptide-8
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01750346
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00487591
Drug: Omacor (omega-3-acid ethyl esters)plus simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omacor(omega-3-acid ethyl esters) - 4/g day (4 one gram capsules) simvastatin - 20 mg/day (1 tablet/20 mg)
Trial: NCT00487591
Drug: simvastatin plus placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin 20mg/day (1 tablet 20 mg)plus 4 capsules matching placebo
Trial: NCT00473343
Drug: Metvix® cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01136655
Drug: 80/2.25 μg Symbicort pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhalation
Trial: NCT01136655
Drug: 80/4.5 μg Symbicort pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhalation
Trial: NCT01136655
Drug: Foradil Aerolizer 12 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhalation
Trial: NCT01136655
Drug: placebo HFA pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhalation
Trial: NCT00704353
Drug: Standard Medical Care (SMC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per product label
Trial: NCT03195088
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection
Trial: NCT04499963
Drug: Theracurmin HP
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention is based on the twice daily dosage of Theracurmin 90 mg capsules used in a trial of patients with mild cognitive impairment
Trial: NCT03982004
Drug: Intra-lesional GM-CSF
RxNorm normalized name: scabies lesion lysate (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mcg every 2 weeks x 3 doses then every 3 weeks for 3 doses
Trial: NCT03216096
Drug: Placebo ophthalmic solution and 3% DE-089 ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ophthalmic solution; 1 drop, 6 times daily (every 2-3 hours) instilled into both eyes for 2-week run-in period 3% DE-089 ophthalmic solution; ; 1 drop, 6 times daily (every 2-3 hours) instilled into both eyes for 4-week treatment period
Trial: NCT01774435
Drug: EN3342
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00263029
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500mg tablets and 150mg tablets. 750mg/m² bd given approximately 12 hours apart
Trial: NCT01289236
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet (placebo) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period.
Trial: NCT01981655
Drug: Hartmann's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hartmann's solution of 3 ml per kg BW is administered in 15 minutes, No infusion thereafter i.e. in total 3 ml per kg over 24 hours
Trial: NCT03034564
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01673711
Drug: deuterated phenanthrene tetraol
RxNorm normalized name: pentaerythrityl tetraoleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01673711
Drug: pharmacological study
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Correlative studies
Trial: NCT03572777
Drug: Concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin ('Amoksicilin') 1 g bid 14 days.
Trial: NCT03572777
Drug: Concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin ('Makcin') 500 mg bid for 14 days
Trial: NCT03572777
Drug: Concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole ('Medazol') 500 mg bid for 14 days
Trial: NCT03572777
Drug: Concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole ('Emanera') 40 mg bid for 14 days
Trial: NCT03572777
Drug: Hybrid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin ('Amoksicilin') 1 g bid 14 days
Trial: NCT02676089
Drug: CHF 1535 200/6 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03572777
Drug: Hybrid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole ('Emanera') 40 mg bid for 14 days
Trial: NCT03572777
Drug: Hybrid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin ('Makcin') 500 mg bid for the last 7 days
Trial: NCT03572777
Drug: Hybrid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole ('Medazol') 500 mg bid for the last 7 days
Trial: NCT00940693
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one capsule of placebo taken one a day for 6 weeks
Trial: NCT00610987
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomly assigned to one of two groups. Both groups will receive 1 gram (g) of IV cefazolin prior to incision, per standard protocol at our institution. A 2-g dose of cefazolin will be administered IV for patients weighing more than 80 kg. A second 1-g dose of cefazolin will be given three hours later if the patient is still in the operating room. Upon completion of the surgical procedure, Group II will receive no additional antibiotic. Instead, they will receive normal saline injection every eight hours as a placebo.
Trial: NCT00050609
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet taken by mouth once a day for 8 weeks
Trial: NCT03116698
Drug: High dose DFD07 once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose DFD07 once daily
Trial: NCT03116698
Drug: High dose DFD07 twice daily
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High dose DFD07 twice daily
Trial: NCT03116698
Drug: Placebo twice daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily
Trial: NCT03001089
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
Trial: NCT01483781
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form = capsules, route = oral use. One capsule once daily for up to approximately 85 days (approximately 12 weeks)
Trial: NCT00432614
Drug: SR58611A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT00432614
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT01155362
Drug: Vehice Control
RxNorm normalized name: SUSPENDING VEHICLE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003398
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04360551
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily
Trial: NCT02386436
Drug: GSK2330811
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2330811 will be supplied as clear or opalescent, colourless, yellow to brown liquid administered as single dose s.c.
Trial: NCT02386436
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be supplied as Normal Saline (0.9% weight by volume \[w/v\] Sodium Chloride) administered as single dose s.c.
Trial: NCT00520884
Drug: Ghrelin Infusion - Healthy
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At time 0, a graded infusion of Ghrelin of 2.5, 5.0, and 10.0 pmol/kg/min infused in one of the IV sites for 60 minutes each, totalling 180 minutes when the infusion will be stopped.
Trial: NCT00982865
Drug: MSC1936369B
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02998775
Drug: Plasma Sampling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.
Trial: NCT02152332
Drug: JNJ-54861911-Therapeutic Dose
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-54861911 50 mg once daily for 7 days in all treatment sequence.
Trial: NCT03151863
Drug: Opioids
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The usual opioid treatment used for nursing care
Trial: NCT02645409
Drug: OTL38
RxNorm normalized name: Fluorodeoxyglucose F 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTL38 is a folate analog conjugated with a fluorescent dye that emits light in the near infrared spectrum. This longer wavelength allows for deeper penetration of the fluorescent light through tissues with the potential to better image tumors beneath adipose tissue or deeper into organ parenchyma.
Trial: NCT01615198
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo of LCZ696 tablet, matching placebo of Olmesartan capsule
Trial: NCT01615198
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg, 200 mg tablets
Trial: NCT03852251
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will receive AK104 in combination with oxaliplatin and capecitabine.
Trial: NCT03426371
Drug: KL-140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KL-140 will be administered every 7 days at an initial dose of 400 milligram per square meter (mg/m\^2) at 5 milligram per minute (mg/min) and 250 mg/m\^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity to KL-140.~Drug: Oxaliplatin Oxaliplatin 85 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: Folinic Acid FA 200 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: 5Fluorouracil 5-FU as a bolus of 400 mg/m\^2/day intravenously followed by 2400 mg/m\^2/day infusion over 48 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
Trial: NCT03426371
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered every 7 days at an initial dose of 400 milligram per square meter (mg/m\^2) at 5 milligram per minute (mg/min) and 250 mg/m\^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity Drug: Oxaliplatin Oxaliplatin 85 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: Folinic Acid FA 200 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: 5Fluorouracil 5-FU as a bolus of 400 mg/m\^2/day intravenously followed by 2400 mg/m\^2/day infusion over 48 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
Trial: NCT02833974
Drug: Placebo Nasal Spray Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal Spray Solution as for GSK2245035 without active ingredient.
Trial: NCT01593293
Drug: PemCarbo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500mg/m2, Carboplatin AUC5 intravenously q 3 weeks for 4 cycles, followed by pemtrexed 500mg/m2 q 3 weeks for maintenance therapy
Trial: NCT04290858
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted concentration will have a tidal oscillation between 100 and 300 ppm, in order to maintain an average inhaled concentration from 140 to 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or trough a non-rebreathing mask without positive end expiratory pressure, depending on the clinical needs of the patient.
Trial: NCT03161054
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction Phase: Cyclophosphamide 50 mg/day will be orally administered from day 1 to day 21 (after dinner).~Maintenance Phase: 50 mg/day will be orally administered from day 1 to day 14 (after dinner).
Trial: NCT00585143
Drug: ABT-335
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg once daily for 10 consecutive days
Trial: NCT00585143
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg once daily for 10 days
Trial: NCT01579188
Drug: GV1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection 0.84 mg ± 0.084 mg 3 times in Week 1 (Monday, Wednesday, and Friday) and once (Mondays) in Weeks 2, 3, 4, 6, 8, and 10, followed by boost injections given on Weeks 14, 18, 22, 26, and thereafter at 12 week intervals up to Week 98
Trial: NCT01579188
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two injections of normal saline injected in the same manner as the experimental drug, GV1001
Trial: NCT03902509
Drug: basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glucocorticoid and expectant treatment etc.
Trial: NCT00177775
Drug: MucoMilk product
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03703882
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00625833
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet once a day dosing for 10 weeks.
Trial: NCT00747643
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in this group received a placebo and did not receive any active medication according to the schedule in the Arm Description.
Trial: NCT03632798
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapies chosen by Physician or ChemoID assay are in the same list of FDA approved drugs to treat recurrent ovarian cancer.~Chemotherapy list:~* Liposomal Doxorubicin;~* Docetaxel;~* Paclitaxel;~* Carboplatin;~* Cisplatin;~* Gemcitabine;~* Topotecan;~* Carboplatin, Gemcitabine;~* Cisplatin, Gemcitabine;~* Carboplatin, Liposomal Doxorubicin;~* Carboplatin, Paclitaxel;~* Carboplatin, Docetaxel.
Trial: NCT02956954
Drug: Enzyme replacement therapy (Agalsidase alpha (Replagal®))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient treated with Enzyme replacement therapy as usual (Agalsidase alpha (Replagal®)). The treatment is prescribed in routine and not specially for the protocol
Trial: NCT01086462
Drug: GSK2239633
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ug GSK2239633 containing approximately 10kBq \[14C\]-GSK2239633
Trial: NCT00907348
Drug: LR-CHOP21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIRST DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 5 mg/day D1-D14~SECOND DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1;Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 10 mg/day D1-D14~THIRD DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 15 mg/day D1-D14~FOURTH DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 20 mg/day D1-D14 Repeated every 21 days
Trial: NCT03321136
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing mannitol looking identical to the other drugs.
Trial: NCT02955940
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine at the same dose provided in the parent study at the time of the rollover.
Trial: NCT03171220
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide(CTX) 300mg/m2/d×3d，3 days prior to each NRTs infusion as preconditional chemotherapy.
Trial: NCT01517711
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be self-administered by oral route every morning (with or without food) for 6 weeks. Patients will be instructed to take it the same way (either with food or without food) each time they take their dose. Each patient will be provided with 1 week supply of Tramadol ER or matching placebo on visits 2 (week 0) and 3 (week 1) and 2 weeks supply on visits 4 (week 2) and 5 (week 4).
Trial: NCT01120002
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two Tamibarotene 2 mg or placebo tablet per day, once daily.
Trial: NCT03236311
Drug: SAR407899
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Capsule Route of administration: Oral
Trial: NCT03236311
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Capsule Route of administration: Oral
Trial: NCT03236311
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Trial: NCT01035385
Drug: FOFLOX4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX4:Oxaliplatin 85mg/m2 ivgtt d1 2hr calcium leucovorin:200mg/m2 ivgtt d1 d2 2hr fluorouracil:400mg/m2 iv d1 d2 fluorouracil:600mg/m2 civ d1 d2 22hr 2 weeks repeated one cycles
Trial: NCT02900443
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03575234
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV